GW Pharmaceuticals — Shareholder Meeting (March 2017)
35 slides from GW Pharmaceuticals's shareholder meeting presentation, Mar 14, 2017
Slide 1: Annual General Meeting March 2017
©2017 GW Pharmaceuticals plc | All Rights Reserved Annual General Meeting March 2017
Slide 2: Forward-Looking Statements
FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements that are based on our management’s beliefs and assumptions and on information currently available to management . Forward - looking statements include information about our current expectations for future events, in
Slide 3: Agenda
• 2016 Highlights Justin Gover, CEO • Clinical Update Dr. Stephen Wright, CMO • US Launch Preparation Julian Gangolli, President North America • Manufacturing and EU Commercialisation Chris Tovey, COO • Financial Update Scott Giacobello, CFO • 2017 Newsflow Justin Gover, CEO Agenda GW Pharmaceutical
Slide 4: 2016 Highlights
• Epidiolex ® (CBD) - Positive results in Phase 3 Dravet syndrome trial and two pivotal Phase 3 LGS trials - Positive pre - NDA meetings held with FDA - NDA submission for both Dravet and LGS indications expected mid - 2017 - EU regulatory submission planned for H2 2017 - Manufacturing scale - up on
Slide 5: Clinical Update
Clinical Update
Slide 6: Epidiolex Phase 3 Program Overview
Epidiolex ® Phase 3 Program Overview 6 > 97% of completers continued into OLEX March 2017 GW Pharmaceuticals plc Investor Presentation Physician Sponsored GW Sponsored Dravet Syndrome Lennox - Gastaut Syndrome Tuberous Sclerosis Complex Infantile Spasms Childhood Epilepsy Syndromes 2015 2016 2017 Ph
Slide 7: 1st Phase 3 LGS Study Principal Efficacy Results
1st Phase 3 LGS Study Principal Efficacy Results GW Pharmaceuticals plc Investor Presentation 7 44 49 22 20 0 10 20 30 40 50 60 Treatment Period Maintenance Period Median % Reduction 41 45 14 15 0 5 10 15 20 25 30 35 40 45 50 Treatment Period Maintenance Period Median % Reduction Drop Seizures Total
Slide 8: 1st Phase 3 Dravet Syndrome Study Principal Efficacy Results
39 41 13 16 0 5 10 15 20 25 30 35 40 45 Treatment Period Maintenance Period Median % Reduction 29 37 9 10 0 5 10 15 20 25 30 35 40 Treatment Period Maintenance Period Median % Reduction 1st Phase 3 Dravet Syndrome Study Principal Efficacy Results GW Pharmaceuticals plc Investor Presentation 8 p=0.01
Slide 9: 2nd Phase 3 LGS Topline Efficacy Results
2nd Phase 3 LGS (Multiple Dose Study) Topline Efficacy Results GW Pharmaceuticals plc Investor Presentation 9 42 37 17 0 5 10 15 20 25 30 35 40 45 Treatment Period Median % Reduction 20mg/kg/day CBD (n=76) 10mg/kg/day CBD (n=73) Placebo (n=76) p=0.0047 p=0.0016 Drop Seizures March 2017 Source: GW pr
Slide 10: Phase 3 Global Impression of Change
Phase 3 Global Impression of Change GW Pharmaceuticals plc Investor Presentation 10 March 2017 17.9 16.7 23.8 32.1 8.3 1.2 0 5.9 10.6 17.6 50.6 10.6 2.4 2.4 0 10 20 30 40 50 60 Very Much Improved Much Improved Slightly Improved No Change Slightly Worse Much Worse Very Much Worse Percentage of Patien
Slide 11: Phase 3 Responder Analysis
Phase 3 Responder Analysis GW Pharmaceuticals plc Investor Presentation 11 LGS 1 Dravet syndrome 1 March 2017 Source: American Epilepsy Society 2016 Annual Meeting posters 20 mg/kg/day CBD (n=86) Placebo (n=85) 20 mg/kg/day CBD (n=61) Placebo (n=59)
Slide 12: Phase 3 Safety Profile
Phase 3 Safety Profile • Consistent AE profile across pivotal, EAP and state programs. Most common AEs (>10% of patients) in Phase 3 trials include: - Somnolence, diarrhea, decreased appetite, fatigue, pyrexia, vomiting, lethargy, upper respiratory tract infection, convulsion • SAEs consistent with
Slide 13: Comprehensive NDA Submission Package
Comprehensive NDA Submission Package • Extensive FDA interactions throughout EAP and Phase 3 program - Clinical and pre - clinical pre - NDA meeting held in July 2016 - Proposed pre - clinical and clinical content of the NDA submission was confirmed - CMC pre - NDA meeting held in November 2016 - Pr
Slide 14: CBDV Program
• CBDV has shown anti - epileptic properties across a range of in vitro and in vivo animal models of epilepsy and different from CBD - CBDV looks to be differentiated from CBD in four key ways: efficacy profile in seizure models, metabolic profile, pharmacological profile and has different physico -
Slide 15: THC:CBD in Glioblastoma
• THC:CBD investigational product candidate for the treatment of GBM - Orphan Drug Designation from FDA • GBM is the most common and most aggressive type of malignant primary brain tumor - Typically patients succumb to the disease approximately 15 months after diagnosis - Treatment for GBM remains c
Slide 16: US Launch Preparation
US Launch Preparation
Slide 17: US Market Overview
• US is the world’s largest pharmaceutical m arket • Heavily regulated from a compliance perspective - Interactions with Health Care Professionals - Financial and Accounting reporting standards - Reporting to both individual State and Federal agencies • US physicians have broad latitude to prescribe
Slide 18: Significant Unmet Need in Epilepsy
• 2.2 million U.S. patients with epilepsy (470,000 children) - ~ One third of patients are pharmacoresistant with seizures persisting despite multiple antiepileptic drugs (AEDs) • Childhood - onset epilepsy - Multiple distinct orphan syndromes, almost none with a specific indicated therapy - Many sy
Slide 19: Greenwich Biosciences Inc.
• In the U.S. we will use our subsidiary, Greenwich Biosciences Inc., to commercialize our products • New offices recently opened in Carlsbad, CA to accommodate US team • Senior commercial organization in place, many of whom have deep previous epilepsy experience • Key functions include…… - “ High -
Slide 20: AES Scientific Exhibit Engagement
12/4/2016 AGM 20 416 attendees at the Scientific Exhibit 445 downloads of GW sponsored posters >300 attendees to the Innovation Pavilion 416 attended GW Scientific Exhibit >1000 total interactions/reach to KOLs
Slide 21: Medical Affairs Key Priorities for 2017
• Build - out Medical Science L iaison team to 15 people by mid 2017 - Coverage of major US Epilepsy and Academic Medical Centers • Publish and externalize phase 3 and EAP (compassionate use program) data - Peer reviewed journals, posters at major congresses, compendium content • Cannabinoid Educati
Slide 22: Commercial Team Key Priorities for 2017
Market Access • Payer Insight Generation • Value Proposition Development • Payer Discussions Health Economics Outcomes Research - HEOR • Burden of Illness Study • Reimbursement Dossier & Budget Impact Model • Cost of Seizures Supply Chain & Distribution • Specialty Third Party Logistics Provider and
Slide 23: Never losing focus of what matters most... the patients
23 N ever losing focus of what matters most … the patients GW Pharmaceuticals plc Investor Presentation
Slide 24: Manufacturing & Europe Commercialisation
Manufacturing & Europe Commercialisation
Slide 25: Commercial Manufacturing
Commercial Manufacturing Growing & Harvesting Drying & Processing Crystallisation (API) Drug Product Manufacture Bottling & Labeling GMP Non - GMP • GW has operated under commercial GMP licenses issued outside the U.S. since 2005 • Manufacturing scalable through in - house and 3 rd party facilities
Slide 26: Commercial Manufacturing Scale Progress
Commercial Manufacturing Scale Progress In 2017 2016 2016 GW Pharmaceuticals plc Investor Presentation 26 March 2017
Slide 27: Commercial Manufacturing Scale Progress
Commercial Manufacturing Scale Progress In 2017 2016 2016 2017 GW Pharmaceuticals plc Investor Presentation 27 March 2017
Slide 28: Europe is big and diverse
Europe is big and diverse 510 population (million) 24 languages 1 regulatory authority 22% global GDP 28 reimbursement authorities 28 countries GW Pharmaceuticals plc Investor Presentation 28 March 2017
Slide 29: Seizing The European Opportunity
Seizing The European Opportunity 29 Market Opportunity Pricing & Reimbursement Competitors in market Orphan Strong medical education Patient support program Epilepsy medication Strong Patient Advocacy Strategic targeting Supply & Distribution Scientific Excellence Great Data Great People Strong mark
Slide 30: 2017 Imperatives In Europe
2017 Imperatives In Europe Hire Great People • GW is building a strong team in Europe • Robust knowledge in epilepsy & orphan drugs • Relationships in epilpesy community • Recent EU launch experience KOL Development & Data Dissemination • KOL & key centre mapping • Build on clinical trials programme
Slide 31: Financial Update
pharmaceuticals
Slide 32: CFO and US Corporate Governance Transition
• 25 years of financial and operational expertise - Most recently and until its acquisition by Allergan, Inc. in late 2016, served as Chief Financial Officer for Chase Pharmaceuticals Corporation - From 2008 through 2015, senior level finance positions at Allergan, Inc., including VP Finance for Glo
Slide 33: Key Financial Data
Key Financial Data March 2017 GW Pharmaceuticals plc Investor Presentation 33 Clean up ICON Cash at 31 December 2016 $ 444.6m 2017 cash outflow guidance ($ 30m Capex, $ 100m – $120m Opex) $130m – $150m Share Capital Current Options Fully Diluted ADS/m 25.3 0.9 26.2
Slide 34: Upcoming Milestones/Newsflow
Upcoming Milestones/Newsflow GW Pharmaceuticals plc Investor Presentation 34 March 2017 Expected Timing EPIDIOLEX REGULATORY NDA submission with FDA Mid - 2017 EMA submission H2 2017 EPIDIOLEX DATA Dravet Phase 3 data publication Q1 2017 2nd LGS Trial data presentation Q2 2017 Infantile spasms trial
Slide 35: Thank You
Thank You GW Pharmaceuticals plc NASDAQ: GWPH Stephen Schultz, VP Investor Relations sschultz@gwpharm.com + 1 401 - 500 - 6570
GW Pharmaceuticals — Shareholder Meeting (March 2017) on 6ix